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Abstract 
Lipopolysaccharidc (LPS)-induced (i.v. or i.c.v., 1.8 mgjkg) release of von Willebrand factor (vWF) ·was examined in 
spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats. SHR rats releascd significantly (P < 0.05) more 
vWF than WKY rats in response to LPS. LPS also inhibited factor VIII procoagulant activity (FVIII: c) which may indicate an 
increase in thrombin activity. Cultured cerebrovascular endothelial cells (EC) derived from both SHR and WKY rats, as weil as 
human umbilical vein EC (HUVEC) cultures constitutively released vWF. Treatment with agonists including LPS, thrombin and 
tumor necrosis factor-a (TNFa) did not affect the in vitro secretion of vWF by cerebrovascular EC cultures but significantly 
upregulated vWF release by HUVEC cultur~s. Preincubation of cerebrovascular EC cultures with interleukin-1 OL-l) ± TNFa 
or co-culturing in the presence of LPS-activated syngeneic monocytes had no effect on vWF secretion. The findings demoostrate 
that conditions of hypertension may affect endothelial cells and make them more responsive to agonist Stimulation and thereby 
increase secretion of vWF, an important factqr in hemostasis as weil as thrombosis. The capacity of LPS to significantly affect the 
in vivo secretion of vWF in SHR and WKY rats but not cultured cerebrovascular EC indicates that observed elevations in plasma 
vWF were not derived from cerebrovascular EC. lt is suggested that hypertension may function as a risk factor for thrombotic 
stroke by influencing factors involved in coagulation processes, such as vWF and factor VIII : c. 
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1. Introduction 
Although hypertension has been identified as a risk 
factor for stroke, the mechanism by which it functions 
as a predisposing agent is unclear [8]. lt has been 
shown that rats with stroke risk factors, such as hyper-
tension, diabetes and advanced age, have significantly 
higher incidences of stroke than control rats when 
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challenged with a single dose of lipopolysaccharide 
(LPS) [12]. In addition, spontaneously hypertensive 
(SHR) rats injected (i.v. or i.c.v.) with LPS produced 
more TNFa in both blood and ccrebrospinal fluid 
samples than normotensive (Wistar-Kyoto, WKY) rats 
[31]. Hypertension may function as a stroke risk factor 
by altering endothelium to render it more proinflam-
matory and procoagulant. In hypertensive animals, seg-
ments of the vasculature can upregulate the expression 
of adhesion receptors, such as ICAM-1 [32] and circu-
lating blood cells, can bind and. accumulate locally. 
Monocytes that accumulate· in a pcrivascular location 
[3,32] expose the adjacent endothelium to the potential 
for periodic activation by cytokines, such as inter-
leukin-1 {IL-1) and tumor necrosis factor-a (TNFa). 
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These cytokines arc sufficient to "prepare" the vessel 
segment for a localized Shwartzman reaction [21] and a 
process related to this paradigm could underlic the 
increased probability of stroke due to thrombosis 
andjor hemorrhage that accompanies hypertension 
[12]. 
An important factor expressed by vascular endothe-
lium which plays a critical roJe in hemostasis as weil as 
thrombosis is von Willebrand factor (vWF) [28,36]. This 
factor is known to mediate platelet adhesionjaggrega-
tion and thrombus formation by interaction with 
platelets [36]. Endothelial cells (EC), megakaryocytes 
and platelets are the only cell typcs known to synthe-
size and secrcte vWF [16,34]. EC can secrete vWF by 
both a constitutive pathway linked to synthesis and a 
regulatory pathway which can be induced by a variety 
of agonists and utilizes vWF stored in Weibel-Palade 
bodies [13,18,19,23,28,29,35]. 
In addition, vWF also functions as a carrier for the 
procoagulant factor (FVIII: c) in circulating blood [15]. 
FVIII : c normally circulates in plasma in an inactive 
form noncovalently bound to vWF which protects 
FVIII : c from enzymatic degradation and stabilizes its 
procoagulant activity [37]. Activation of coagulation 
includes dissociation of vWF jFVIII : c complex and 
activation of FVIII : c by serine proteases, such as 
thrombin [9]. Since thrombin can also inactivate 
FVIII : c [9] (by activating protein c) and enhance vWF 
secretion [ 13,23,29], an increase in the ratio between 
vWF and FVIII : c may be utilized as an indicator of 
thrombin generation and activation of hemostatic 
mechanisms [5]. 
In the present paper, we investigated the hypothesis 
that hypertension may increase the probability of local 
thrombosis or hemorrhage by enhancing the sensitivity 
of endothelium to factors capable of generating a pro-
coagulant state. We have examined how LPS (i.v. and 
i.c.v.) affects the in vivo secretion of vWF in SHR and 
WKY rats. In addition, we examined the effect of LPS 
and other potentially relevant physiologic factors on 
the secretion of vWF by cultured EC derived from 
SHR and WKY rats. Finally, the effect of LPS on 
FVIII : c Ievels was also compared in these two strains 
of animals to compare their procoagulant potential. 
2. Materials and methods 
2.1. Animals 
SHR and normotensive WKY rats 00-16 weeks old) were ob-
tained from Taconic Farms (Germantown, NY). All rats were housed 
for 3-5 days after delivery with food and water ad libitum at 
20-22°C, 50% humidity and 12/12 h Iight/dark cycles. The experi-
ments described here were performed in accordance with guidelines 
put forth in the Guide for the Care and Use of Labaratory Animals 
(DHEW Publication NIH 85-23, 1985). 
2.2. Surgical procedures 
l.v. and i.c.v. injections of the LPS ( E. culi LPS 0111:84, phenol 
extract; Sigma, St. Louis, MO) were performcd as described by Sirt~n 
et al. [31]. The proper position of thc i.c.v. cannula was ascertained 
at the end of the experiment by an injcction of mcthylcne blue (5 p_l) 
into the ventricular space. The rats were allowed to recover in single 
cages with food and water and regained consciousness within I 0 min 
of the end of the procedure. Each animal received only one injection 
of LPS. Arterial blood samples from rats anesthetized with pheno-
barbital (50 mgjkg i.p.) were collected at indicated time points after 
LPS injection. A laparotomy was performed and blood was with-
drawn via a sterile syringe (containing 0.1 M sodium citrate) from the 
abdominal aorta. All samples were centrifuged at (2000 x g, 5 min) 
and the plasma was removed and stored at - 70°C. 
2.3. rWF assays 
The vWF concentration in the plasma of WKY and SHR rats and 
in the conditioned media of all cultured EC was measured by an 
ELISA kit (Asserachrom. Amcrican Bioproducts, Parsippany, NJ). 
This assay was previously shown to cross-react with the rat vWF [6). 
The lower Iimit of sensitivity of the assay was 10 ngjml, assuming a 
vWF concentration in human plasma of 10 p.gjml [15). EC were 
grown to confluence, washed three times with phenol red-free and 
calcium-free Ml99 media (Biofluids, Rockville, MD), supplemented 
with 3 mM CaCiz. 2 mM glutamine, 20 mM hepes, antibiotic-anti-
mycotic mixture and 2% BSA and incubated with 50 p.l of either 
media alone or indicated concentrations of LPS, calcium ionophore 
A23187, thrombin, phorbol myristic acid (PMA), IL-1, TNFa for 
fixed periods of time at 37°C in a humidified atmosphere in 5% C02. 
In indicated experiments. EC cultures contained cycloheximide (1 
p.gjml). Media for vWF determinations were removed from cach 
weil and immediately frozen at - 7ooc. 
2.4. Factor Vl/l:c assay (COATEST) 
The coagulating activity of FVIII: c was assessed by a two stage-
assay (COATEST kit) based upon the stimulatory effect of FVIII:c 
on the generation of Xa in the presence of IX, X, phospholipids and 
calcium, which results in the formation of free-nitroaniline (mea-
sured at 405 nm) and rcflccts the FVIII: c activity [26). Briefly, 
100-p.l samplcs of either test plasma or standard (pooled normal 
human plasma) were incubated (5 min, 37°C) with 200 p.l of a 
mixturc of factor IXa, X and phospholipid followed by 100 p.l of 
0.025 M CaCI 2• After a second 5-min incubation, 200 }LI of the 
chromogenic and highly selective factor Xa substrate S-2222 [1) was 
added and, after a 5-min incubation, the reaction was stopped by the 
addition of 100 p. I of 50% acetic acid. The volumc was adjusted to I 
ml and the FVII I: c activity was assessed by measuring the ab-
sorbance at 405 nm. No differences were found when human and rat 
standard curves were compared for the COATEST activity. 
2.5. EC preparatiun and cultur<! 
Cerebrovascular EC were isolated following the procedures de-
scribed by Doron et al. [6]. Five WKY and SHR rats {16-22 weeks 
old) wcre utilized for each preparation, which were ultimately resus-
pended in Ml99 (Biofluids) containing 20% heat-inactivated FCS, 2 
mM glutamine, 90 }Lgjml heparin (Calbiochem, La Jolla, CA), 20 
p.gjml EC growth supplcment (Sigma), 1 X antibiotic-antimycotic 
mixture (Gibco). The freshly isolated EC were platc:d (- 1 x 104 /100 
p.ljwcll) on 96-well microtiter plates precoated with Matrigel (Col-
laborative Research, Bedford, MA) as previously described [6]. HU-
VEC were obtained from Clonelies (San Diego, CA) and were 
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cultivated under conditions similar to those described above for 
cerebrovascular EC. 
Confluent cerebrovascular EC and HUVEC cultures exhibited 
characteristic cobblestone appearance and cell viability were > 95% 
as determined by the trypan blue exclusion technique. All cell 
cultures contained > 90% EC as determined by immunocytochemi-
cal staining using antibody to vWF (FVIIIR: Ag) (Accurate Chemical 
and Scientific, Westbury, NY). 
2. 6. Monocyte preparation 
Peripheral blood monocytes were prepared from blood (obtained 
by i.c. puncture of SHR and WKY rats) by density gradient centrifu-
gation using HISTOPAQUE (Sigma). All monocytejpreparations 
were phenotypically characterized by staining with monocytejmacro-
phage specific antiborlies (Mac-1 and ED-1; Aceurate Chemical and 
Scientific). Monocyte preparations were cultured (2 h) in the pres-
ence or absence of LPS (10 ng;mO and added to EC monolayers at 
indicated concentrations .. Monocyte culture supernatants were also 
concomitantly harvested and frozen ( -70°C) until use. 
2. 7. Statistical analysis 
Statistical analysis consisted of one-way ANOV A followed by 
Bonferroni correction. Statistkai significance was accepted at P < 
0.05; values are presented as mean ± S.E.M. or S.D., as indicated. 
When ANOV A revealed significant differences, Student-Newman-
Keuls test was used to analyse differences within individual groups. 
3. Results 
3.1. Effect of LPS i.v. 
The effect of LPS on vWF plasma Ievels was exam-
ined following i.v. injection. SHR rats injected (i.v.) 
with a single dose (1.8 mgjkg) of LPS exhibited a 
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Fig. 1. Time response of changes in plasma Ievel of vWF after an i.v. 
injection of sterile saline or LPS (1.8 mgjkg) in SHR rats. Values 
indicate mean ± S.E.M. ANOV A revealed a significant interaction 
(time vs. treatment) for effect of LPS at 2 h postinjection. * P < 0.01 
LPS compared with vehicle-treated group (Student-Newman-Keuls 
test). 
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Fig. 2. Dose-response effect of LPS on serum vWF in SHR and 
WKY rats. Rats were injected with sterile saline, 0.1 or 1.8 mgjkg 
LPS by i.v. (A) or i.c.v. (B) routes. Values (mean ± S.E.M.) represent 
Ievels of vWF after 2 h injection of LPS or sterile saline. * P < 0.01 
LPS compared with vehicle-treated group (Student-Newman-Keuls 
test). + P < 0.05 compared with WKY rats injected with 1.8 mgjkg 
LPS (Student-Newman-Keuls test). 
maximum response (vWF release) of 46% increase 
above background (P < 0.01) at a time period of 2 h 
after injection (Fig. 1). The vWF Ievels at 15 min or 4 h 
after injection were not significantly different from 
controls (injected i.v. with sterile saline) (Fig. 1). A 
similar time course of vWF release was observed with 
WKY rats. 
To directly compare the responsiveness of SHR and 
WKY rats, vWF Ievels in plasma were measured at 2 h 
after i.v. injection of different doses (0.1 and 1.8 mgjkg) 
of LPS. The results showed that SHR rats released 
significantly ( P < 0.05) more vWF than WKY rats when 
injected with 1.8 mgjkg LPS. No elevation in the Ievels 
of released VWF were observed at the lower dose of 
LPS (0.1 mgjkg) in either SHR or WKY rats (Fig. 2A). 
3.2. Effect of LPS i.c.u. 
LPS injected i.c.v. also elevated vWF Ievels (Fig. 
2B). Similar to observations with i.v. injections, signifi-
cant differences in the Ievels of vWF release between 
SHR and WKY rats were only observed at the higher 
concentration of LPS (1.8 mgjkg). SHR rats produced 
more vWF (23% increase above background; P < 0.05) 
as compared with WKY rats (11% increase above 
background). The increased plasma Ievels of vWF in 
SHR rats injected with this concentration of LPS were 
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Table 2 
Effects of various substances on release of vWF in HUVEC cultures 
Treatment lncubation time (h) a 
0.5 4 8 
Media 2.81 ± 0.26 4.75 ± 0.39 18.28 ± 1.22 69.78 ± 4.31 
LPS (10 ngjml) 3.25 ± 0.48 8.83 ± 0.60 * 21.57 ± 1.46 * 73.44 ± 4.81 
LPS 000 ngjml) 3.63 ± 1.28 8.72 ± 1.98 * 22.89 ± 1.49 * 70.08 ± 5.83 
Thrombin (I U jml) 6.11 ± 0.55 * 10.80 ± 0.89 * 35.32 ± 2.28 * 68.79 ± 4.46 
Thrombin (10 U jml} 6.29 ± 0.48 * 12.01 ± 0.90 * 37.58 ± 3.02 * 72.32 ± 6.02 
PMA (100 ngjml) 13.33 ± 1.03 * 24.11 ± 1.98 * 29.80 ± 1.97 * 67.08 ± 6.57 
TNF+ IL-1 2.71 ± 0.96 4.87 ± 0.43 24.48 ± 2.00 * 66.71 ± 5.57 
A23187 (100 ngjml) 2.63 ± 0.17 4.42 ± 0.19 20.34 ± 1.80 61U2 ± 4.03 
a Values for vWF are presented as ngj105 cells (mean ± S.D.) obtained from three separate wells of a representative experiment out of four 
cxpcriments with similar results. 
* Significant difference of treatment ( P < 0.05, ANOV A) from media alone. 
considerably lower than those observed after i.v. injec-
tion of LPS. 
3.3. Effect of LPS i.v. on FV/1/: c 
It was observed that LPS injected i.v. at a concentra-
tion of 1.8 mgjkg reduced the FVIII: c activity in both 
SHR and WKY rats (Fig. 3A). No significant differ-
ences in the magnitude of the reduction of FVIII: c 
activity wcre observed in both rat strains. The de-
crcased Ievels of FVIII: c along with the significantly 
increased Ievels of vWF released in both strains of rats 
0 140 
L A ~ -+-' c:: 120 0 u R 
0 
+-' 
D 
QJ 
-+-' 
0 
QJ 
L 
u 
> 
LL 
0 
o-
0 
4 8 
u 
> 
LL 
LL 
5 
> 
LPS ( mg I kg) 
Fig. 3. Effect of LPS (1.8 mgjkg) injected i.v. on serum FVIII: c (A) 
and vWF jFVIII :c (B) ratios. SHR and WKY rats were injected (i.v.) 
with sterile saline or 1.8 mgjkg LPS. FVIIl: c and vWF Ievels were 
asscsscd as described in Materials and methods. Values (mean ± 
S.E.M.) represent Ievels of FVIII: c in plasma at 2 h postinjection. 
resulted in increases in the vWF /VIII : c ratio in both 
SHR and WKY rats (Fig. 3B). 
3. 4. Release of v WF by cerebrovascular EC cultures 
Experiments performed on cultured cerebrovascular 
EC indicated' that the concentration of vWF in super-
natant medium gradually increased. This time-depend-
ent increase could be detected as early as 1 h after 
culture. Although the total amount of vWF released 
varied from one culture to another, no significant dif-
ferences were consistently observed between cere-
brovascular EC cultures from SHR and WKY rats. The 
release of vWF could be inhibited by preincubation of 
EC with cycloheximide (results not shown). 
The ability of various agonists to affect the release 
of vWF by cultured cerebrovascular EC was examined 
(Table 1). In all experiments, the rates of vWF release 
by EC treated with these factors were not significantly 
different from control EC cultures incubated in media 
alone. Additional concentrations of LPS (0.1-1 00 
ngjml), thrombin 0-10 U jml), PMA (1 0-100 ngjml), 
TableI 
Effects of various substances on rclease of vWF in SHR and WKY 
EC cultures 
Treatment lncubation time (h) a 
4 
WKY 
Media 6.95±0.95 14.68 ± 1.19 
TNF+IL-1 8.22± 1.61 14.03 ± 2.02 
LPS ( 100 ngjmD 6.78± 1.03 13.92±0.73 
PMA (100 ngjml) ND 15.22±0.81 
Thrombin ( 10 U jml) ND 12.14± 3.02 
SHR 
Media 6.92± 11.61 12.25± 1.26 
TNF+ IL-1 KOti± 1.03 12.87±0.15 
LPS (100 ngjml) 6.65 ± 1.57 12.35 ± 0.73 
PMA (100 ngjml) ND 10.02± 2.81 
Thrombin (10 U jml) ND 10.60±0.84 
" Values for vWF are presented as ngj 105 cells (mean ±S.O.) ob-
tained from three separate wells of a representative experiment out 
of five experiments with similar results. 
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TNFa 0-200 u;rnO and IL-1 0-50 u;rnn had no 
effect on the constitutive release of vWF. Increasing 
the incubation time period to 8-24 h did not result in 
any stimulation in vWF Ievels above controls (results 
not shown). Preincubation of EC cultures with cyclo-
heximide inhibited vWF release under all conditions 
(results not shown). 
3.5. Release of vWF by HUVEC cultures 
Confluent HUVEC cultures constitutively released 
vWF into culture medium at a rate similar to that 
observed with rat cerebrovascular EC (Table 2). In 
addition, pretreatment with cycloheximide also inhib-
ited vWF release in a similar manner. However, unlike 
cerebrovascular EC, treatment of confluent HUVEC 
cultures with various agonists for different time periods 
had significant effects on the Ievels of vWF release 
(Table 2). HUVEC cultures incubated for 1 or 4 h with 
LPS (10 ngjml), thrombin (1 U ;mO or PMA (100 
ngjml) exhibited significantly higher Ievels of vWF 
release than observed in control cultures incubated in 
media alone (Table 2). Incubation with greater concen-
trations did not cause higher vWF Ievels; incubation 
for Ionger periods of time did not result in vWF Ievels 
different from controls (Table 2). No significant eleva-
tion of vWF Ievels above controls were observed in 
HUVEC cultures incubated with A23187 (Table 2). 
The addition of thrombin (10 U jml) or PMA (100 
ngjml} to HUVEC cultures preincubated with cyclo-
hcximide resulted in enhanced release of vWF at Ievels 
comparable to those observed with HUVEC not prein-
cubated with cycloheximide (results not shown). 
3.6. Modulated release of vWF by cerebrovascular EC 
and HUVEC cultures 
Attempts to boost the agonist-mediated release of 
vWF by cerebrovascular EC (as weil as HUVEC) cul-
Table 3 
Effects of pretreatment on thrombin-mediated release of vWF in 
SHR EC and HUVEC cultures 
Pretreatment Treatment Incubation time (h) a 
4 
SHREC 
. Media Media 5.I8±2.27 14.97 ± 1.29 
Media Thrombin 6.02±0.58 13.86± 1.09 
IL-1 Thrombin 7.11 ± 1.21 14.21 ±0.81 
TNF+IL-1 Thrombin 6.60±0.28 16.03±2.22 
HUVEC 
Media Media 6.40± 1.6I 22.35±2.02 
Media Thrombin 12.33 ± 0.12 * 41.46±2.23 * 
IL-1 Thrombin I 1.44 ± 1.35 * 39.20 ± 1.62 * 
TNF+IL-1 Thrombin 10.58 ± 1.28 * 41.92± 2.72 * 
a Valucs for vWF are presented as ngjl05 cells (mean ±S.O.) ob-
tained from three separate wells of a representative experiment out 
of two experiments with similar results. 
* Significant difference ( P < 0.05, ANOV A) from media alone. 
Table 4 
Effects of monocytes on release of vWF in HUVEC cultures 
Treatment 
Control 
Mo:EC b 
0.5: I 
5:1 
Activated Mo: EC c 
Incubation time (h) a 
7.23±0.25 
7.15±0.78 
8.34± 1.72 
4 
18.72 ± 1.37 
18.98 ± 2.37 
22.23 ±2.89 
0.5: l 10.04 ± 0. 75 * 21.78 ± 2.66 
5: I 12.29 ± 1.10 * 24.79 ± 2.61 * 
PMA (100 ngjml) 29.73 ± 1.82 * 33.28 ± 3.09 * 
Monocyte sup. d 6.89±0.98 l9.I2± 1.22 
Activated monocyte sup. d 7.47±0.51 21.62± 1.05 * 
a Values for vWF are presented as ngj105 cells (mean ± S.D.) ob-
tained from three separate wells. 
b Monocytes (Mo) were obtained as described in section 2 and were 
added at indicated ratios at initiation of experiment. 
c Activated Mo were incubated with LPS (10 ngjml) for 2 h prior to 
addition to EC at indicated ratios. 
d Supernalants (sup) from resting and LPS-activated Mo were pre-
sent at a concentration of 25% (v jv) and were added at start of 
experiment. 
* Significant difference of treatment ( P < 0.05, ANOV A) from me-
dia alone. 
tures was performed by preincubation with IL-1 in the 
presence or absence of TNFa (Table 3). The results 
indicate that pretreatment had no effect on either 
constitutive or thrombin-induced vWF release nor did 
it alter the already significant thrombin-stimulated re-
lease of vWF in HUVEC cultures. No response was 
observed with rat cerebrovascular EC. 
The ability of monocytes to mediate enhanced vWF 
release by HUVEC was examined by incubating HU-
VEC with various concentrations of monocytes. Al-
though resting monocytes did not significantly affect 
the secretion of vWF, incubation with LPS-activated 
monocytes dose-dependently enhanced the secretion of 
vWF after 1 h incubation (Table 4). Supernatants from 
activated but not resting monocytes also enhanced 
vWF secretion by HUVEC, albeit to lower Ievels. The 
monocyte-mediated release of vWF by HUVEC was 
not due to Iysis of HUVEC since cell viability was 
unaffected in these experiments. ldentical experiments 
performed on SHR and WKY cercbrovascular EC 
cultures using homologaus resting or LPS-activated 
monocytes failed to detect Ievels of vWF significantly 
above controls (results not shown). 
4. Discussion 
Hypertension, as weil as other strokc risk factors, 
such as atherosclerosis and diabetes, are associated 
with increased subendothelial accumulation of mono-
cytes and macrophages [3,27]. A possible mechanism by 
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which these factors contribute to the increascd inci-
dence of stroke may ultimately involve their capacity to 
convert endothelium from an anticoagulant to a proco-
agulant surface. In addition to LPS, TNFa and IL-1 
are capable of "preparing" tissues for a local Shwartz-
man-like reaction [21] thus rendering the endothelium 
procoagulant [22]. lt has been shown in rats that strake 
risk factors including hypertension prepared brainstem 
tissue (i.e. Shwartzman-like reaction) for the develop-
ment of localized ischemia and hemorrhage after i.v. or 
i.c.v. injection of LPS [12]. In addition, hypertensive 
rats injected with LPS produced more TNFa than 
similarly treated normotensive rats [31 ]. 
lt is known that vWF is synthesized by only two cell 
types, megakaryocytes, platelets and EC [16,34]. 
Mcgakaryocytes and platelets do not constitutively se-
crete vWF; they store vWF in organelies known as 
a-granules and acutely release it in response to platelet 
activation. On the other hand, the secretion of vWF by 
EC, which are known to be the major source of vWF, 
occurs by both constitutive and regulated pathways 
[ 19,28,35]. 
lt is shown here that cerebrovascular EC cultures 
derived from SHR and WKY rats constitutively se-
creted vWF into the medium. Treatment with various 
effectors, such as thrombin and PMA, that are widely 
known to induce release of vWF from cultured EC, 
also had no effect on vWF secretion by either SHR or 
WKY EC cultures (Table 1) [18,19,23]. Treatment of 
HUVEC cultures with these same factors induccd the 
release of vWF in a time-dependent manner (Tablc 2). 
One possible reason for this discrepancy may involve 
the the species andjor anatomical region from which 
the EC were derived. Although vWF has been detected 
in cultured EC derived from different species as weil as 
vascular beds, some of these studies do not specifically 
address induced as opposed to constitutive secretion of 
vWF [16,17,30]. EC derived from !arge vessels, such as 
umbilical veins, possess rod-shaped Weibei-Palade 
bodies which release vWF by the regulated pathway 
[19,28,35]. Weibei-Palade bodies are absent in cul-
tured EC derived from human, rat and mause cerebral 
microvessels [4,7,33] which implies that these microves-
sels might release vWF only by the constitutive path-
way. However, it was recently shown by assessment of 
stained preparations that primary cultures of human 
brain microvessel EC, devoid of Weibei-Palade bodies. 
could be stimulated to release vWF [7]. Previous exper-
iments demonstrating some vWF release in brain mi-
crovascular EC raise the possibility that the amount of 
vWF released is near the detection threshold [6]. 
Various aspects of the acute phase response in man, 
which include eievatians in plasma Ievels of vWF, havc 
been attributed to the cytokines TNFa and IL-1 [24,25]. 
Although these cytokines have been shown to enhance 
vWF release by EC, they had little to no effect on vWF 
release by the HUVEC or SHR and WKY EC cultures 
used here [6,29]. Similar negative findings have been 
also been reported by others [11,23,38]. 
In some experimental conditions where these cy-
tokines had no direct effects on vWF release, they 
modulated vWF secretion stimulated by other factors 
[23]. The ability of additional monocyte factors or 
monocytes themselves to affect vWF release by cul-
tured EC was tested (Table 4). The data demonstrated 
that in vitro activated peripheral blood monocytes and, 
to a lesser extent supernatants from these cells, signifi-
cantly elevated the Ievels of vWF released by cultured 
HUVEC; others have also shown a similar monocyte 
requirement for stimulated release of vWF [11,13]. No 
stimulated release was seen using resting monocytes. 
Similar monocyte co-culture experiments using SHR or 
WKY EC did not demoostrate ariy significant changes 
in constitutive vWF secretion (results not shown). 
The evidence presented here suggests that LPS-in-
duced eievatians in plasma vWF in SHR and WKY 
rats is not derived from cerebrovascular EC. Perhaps, 
the elevated vWF Ievels observed in vivo are from EC 
in other areas of the vasculature which may have been 
exposed to LPS which leaked out of the ventricle and 
into the CSF and bloodstream. It is also possible that 
certain factors may induce release of vWF by EC vivo 
but are not active on cultured EC (i.e. in vivo activity 
may be mediated by as yet unknown intermediates 
which are not present in the in vitro systcm) [28]. 
The results presented here (Fig. 3) also show that 
LPS (i.v.) decreased FVIII: c Ievels in plasma. During 
clotting, the !arge amount of thrombin that is pro-
duced, inactivates FVIII : c and stimulates vWF release 
from endothelium and platelets, which Ieads to in-
creases in the vWF jFVIII : c ratio [9]. These results 
may thereforc indicate an increase in thrombin activity 
[ 13,23,29]. 
Although no differences were observed between hy-
pertensivc and normotensive rats in the Ievels of vWF 
released by cerebrovascular EC in vitro, the in vivo 
experiments provide evidence supporting the hypothe-
sis that the strake risk factor hypertension may gener-
ate a hypercoagulant-hyperthrombotic milieu by en-
hancing interactions with vascular endothelium. The 
possible influence of a variety of other factors such as 
the presence of considerably greater numbers of mono-
cytcs in thc circulation of SHR as opposed to WKY 
rats [31,32] may be an important factor. Also, in addi-
tion to storing vWF in Weibel-Palade bodics, EC store 
P selectin [2,20]. lts expression can be induced within 
minutes by factors which also affect vWF and it may 
mediate adhesion of leukocytes to activated endothe-
Iium [10,14]. Future experiments examining the com-
plex interactions involving vascular endothelium and 
circulating blood cells and soluble factors may help to 
clarify the cxistence of the proposed effects of strake 
R.M. McCarron et al. 1 Brain Research 647 ( /994) 265-272 271 
risk factors and suggest modes of prophylactic inter-
vention. 
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